Trials / Completed
CompletedNCT03141463
Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions
Immune Modulating Effects and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With a History of (Pre) Malignant Cervical Lesions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Immune modulating effects and safety of Vvax001; different dosages will be tested in patients with a history of (pre) malignant cervical lesions.
Detailed description
Vvax001 is a therapeutic cancer vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vvax001 therapeutic cancer vaccine | Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks. |
Timeline
- Start date
- 2017-01-13
- Primary completion
- 2017-11-28
- Completion
- 2017-11-28
- First posted
- 2017-05-05
- Last updated
- 2018-05-03
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03141463. Inclusion in this directory is not an endorsement.